Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Overview of Sensus Healthcare Inc
Sensus Healthcare Inc is a specialized medical device company that has dedicated over a decade to the development of non-invasive treatment solutions using proprietary superficial radiation therapy (SRT) technology. This innovative treatment method is designed for both oncological and non-oncological skin conditions, including various forms of non-melanoma skin cancers and conditions such as keloids, offering a safe and cost-effective alternative to surgical procedures.
Core Technology and Treatment Solutions
The company utilizes a proprietary low energy x-ray radiation system that underpins its SRT technology. This method enables precise targeting of skin lesions while minimizing damage to surrounding tissues. The approach is rooted in extensive research and development, ensuring that each device deployed not only aligns with current clinical standards but also supports a streamlined treatment process. The primary devices in the company’s portfolio are designed to simplify the treatment procedure while ensuring efficacy and patient safety.
Business Model and Revenue Generation
Sensus Healthcare Inc generates revenue primarily through the sale of its specialized SRT treatment devices alongside an associated service program. The revenue model is based on direct transactions with hospitals, oncology centers, and dermatology practices, particularly in the United States. The company’s sales approach integrates product delivery with ongoing support, positioning Sensus as a comprehensive service provider within the medical device industry. This dual-focus on advanced technology and customer service ensures that clients receive not only the equipment but also the necessary operational expertise to maximize treatment outcomes.
Market Position and Industry Significance
Operating within the competitive realm of medical devices, Sensus Healthcare Inc has carved out a niche by focusing on non-invasive superficial radiation therapy. The technology addresses a clear need in the treatment of skin conditions by reducing the potential risks and complications associated with more invasive procedures. With increasing emphasis on patient safety and cost-effectiveness in healthcare, the company’s offerings are well-positioned to provide value within hospital oncology and dermatology departments. Its emphasis on targeted radiation treatment distinguishes its operational approach from other modalities available in the market.
Operational Focus and Customer Base
The company's operational framework is built around delivering effective treatment solutions through both its high-quality devices and a robust support program. The customer base includes major healthcare providers such as hospital oncology departments and specialized dermatology practices. By prioritizing reliability and clinical efficacy, Sensus Healthcare sustains trust within the medical community, ensuring continuous adoption of its technology in outpatient treatment settings.
Clinical Impact and Safety
At the heart of Sensus Healthcare Inc's offerings is a strong commitment to patient safety and treatment efficacy. The non-invasive SRT technique minimizes the need for surgical intervention, thereby reducing recovery times and potential risks associated with more invasive treatments. This clinical approach not only enhances patient outcomes but also supports operational efficiency in healthcare settings by offering a streamlined alternative that aligns with modern treatment protocols.
Competitive Landscape and Differentiation
Sensus Healthcare Inc operates in a dynamic industry where differentiation is critical. The company sets itself apart through its exclusive focus on superficial radiation therapy, a technology with a clear evidential basis in decades of research and clinical application. Although facing competition from traditional and emerging treatment modalities, Sensus leverages its research-backed technology and dedicated service programs to maintain a distinct foothold in the market. Expertise in both technological innovation and customer service elevates its competitive profile as a trusted provider in the non-invasive medical device segment.
Conclusion
In summary, Sensus Healthcare Inc is a specialized medical device entity that combines technological innovation with secure, non-invasive treatment options. Its use of superficial radiation therapy not only underscores advances in medical device innovation but also reflects the company's commitment to enhancing patient care in the treatment of skin conditions. This comprehensive approach, integrating advanced product development with dedicated service programs, positions Sensus Healthcare as a valued participant in a complex and critical segment of healthcare technology.
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced the publication of a prospective study in the Journal of the American Academy of Dermatology, demonstrating a significantly low recurrence rate of keloids after superficial radiation therapy (SRT) post-excision. The study showed a 6.25% recurrence rate at six months, with no recurrences at 24 months for the follow-up group. The study suggests that a single 8 Gy dose of SRT may effectively reduce keloid recurrence, especially in steroid-resistant cases. This research highlights the growing acceptance of SRT in dermatology.
Sensus Healthcare, Inc. (SRTS) reported Q3 2020 revenues of $1.6 million, a decline from $5.8 million in Q3 2019, attributed mainly to COVID-19 impacts. The net loss was $(1.7) million, or $(0.10) per share, compared to a $(0.7) million loss in the prior year. Despite challenges, the company made strategic moves, such as acquiring mobile laser businesses, and appointed Megan Cornish to its Board. They began generating recurring revenues from Sentinel IT Solutions, and sold two SRT-100™ systems in China, looking to expand further in Asia.
Sensus Healthcare (Nasdaq: SRTS) announced the appointment of Megan Cornish to its board of directors, effective January 1, 2021, increasing the board to six members. Cornish brings over a decade of experience in government relations and lobbying, particularly in food distribution and public policy. The CEO, Joe Sardano, highlighted her potential to enhance the company’s efforts in promoting superficial radiation therapy and expanding awareness among healthcare providers and patients. Cornish aims to leverage her background to improve access to non-invasive treatments for skin cancer.
Sensus Healthcare (Nasdaq: SRTS) will host a conference call on November 5, 2020 at 4:30 p.m. ET to discuss its third quarter financial results and provide a business update on recent and upcoming milestones.
The call is accessible via dial-in numbers and will also be webcast live, with a replay available thereafter. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing innovative technologies such as the Sculptura™ system and SRT-100™.
Sensus Healthcare (Nasdaq: SRTS) announced a retrospective study revealing a keloid recurrence rate of only 10.4% at 12 months for patients treated with superficial radiation therapy (SRT) after keloidectomy, significantly lower than the typical rate of over 80% with surgical excision alone. This study, published in the Journal of Clinical and Aesthetic Dermatology, involved 61 subjects and highlighted SRT's effectiveness, confirming its potential as a game-changer for treating keloids. The Kaplan-Meier survival probability cure rate stood at 85.6% from 24 months post-treatment.
Sensus Healthcare, Inc. (SRTS) reported second quarter results for 2020, revealing revenues of $1.2 million, down from $7.5 million in Q2 2019, largely due to COVID-19 impacts. The company experienced a net loss of $2.6 million, or $0.16 per share, compared to a profit of $0.1 million a year prior. Cash reserves increased to $18.9 million. Recent strategic moves include acquiring two mobile laser companies in Florida, aiming to generate $1 million in base revenues over the next year, and expanding marketing efforts post-pandemic.
Sensus Healthcare (Nasdaq: SRTS) has acquired two mobile aesthetic laser companies, Aesthetic Mobile Laser Services and Aesthetic Laser Partners, significantly expanding its dermatology customer base in Florida. These acquisitions are anticipated to generate an additional $1.0 million in revenue over the next 12 months and are immediately accretive to earnings. The new division, Sensus Laser Aesthetic Solutions, will be led by management from the acquired companies, enhancing market reach and technology integration as Sensus plans to introduce its own aesthetic laser products.
Sensus Healthcare (Nasdaq: SRTS) will hold a conference call on August 6, 2020, at 4:30 p.m. ET to discuss its Q2 2020 financial results and provide a business update, including recent and upcoming milestones. Investors can access the call via dial-in numbers or a live webcast. The company specializes in non-invasive treatments for oncological and non-oncological conditions, highlighting its innovative products like the Sculptura™ system and SRT-100™ series, aimed at improving patient quality of life.
Sensus Healthcare (Nasdaq: SRTS) has announced the appointment of Hoi-Bun “Benson” Suen as Vice President of International Sales, focusing on the Southeast Asian market for Superficial Radiation Therapy (SRT) products. Mr. Suen's experience includes nearly 20 years in medical device sales in Asia, contributing to the successful shipment of an SRT-100 system to China. CEO Joe Sardano expressed confidence in Mr. Suen's abilities, highlighting potential growth in shipments of SRT-100 units. Sensus specializes in non-invasive treatment devices targeting oncological conditions.
Sensus Healthcare (Nasdaq: SRTS) announced that CEO Joe Sardano will present at the Re-Engaging Medical Practices in an Era of COVID-19 webinar on July 16, 2020. This event aims to discuss the reopening of medical practices post-COVID-19, exploring revenue recovery, patient engagement, and the adaptation of commercialization strategies. It will include Q&A sessions and panel discussions to share insights and strategies on navigating the changing healthcare landscape. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions.
FAQ
What is the current stock price of Sensus Healthcare (SRTS)?
What is the market cap of Sensus Healthcare (SRTS)?
What is the primary focus of Sensus Healthcare Inc?
How does Sensus Healthcare generate its revenue?
What skin conditions are treated with the company's technology?
What distinguishes Sensus Healthcare's technology from traditional treatment options?
Who typically uses Sensus Healthcare's treatment devices?
How does Sensus Healthcare position itself against competitors?
